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Summary Using immunocytochemical and Western blotting techniques we have demonstrated the presence of
abnormally high levels of p53 protein in 8/24 (33%) of human squamous cell carcinomas (SCC) and 9/18
(50%) of SCC cell lines. There was a correlation between the immunocytochemical results obtained with eight
SCC samples and their corresponding cell lines.
Direct sequencing of PCR-amplified, reverse transcribed, p53 mRNA confirmed the expression of point
mutations in six of the positive cell lines and detected in-frame deletions in two others. We also detected two
stop mutations and three out-of-frame deletions in five lines which did not express elevated levels of p53
protein. Several of the mutations found in SCC of the tongue (3/7) were in a region (codons 144-166)
previously identified as being a p53 mutational hot spot in non-small cell lung tumours (Mitsudomi et al.,
1992). In 11/13 cases only the mutant alleles were expressed suggesting loss or reduced expression of the wild
type alleles in these cases. Six of the mutations were also detected in the SCCs from which the lines were
derived, strongly suggesting that the mutations occurred, and were selected, in vivo.
The 12th mutation GTG-*GGG (valine-*glycine) at codon 216 was expressed in line SCC-12 clone B along
with an apparently normal p53 allele and is to our knowledge a novel mutation. Line BICR-19 also expressed
a normal p53 allele in addition to one where exon 10 was deleted.
Additionally 15 of the SCC lines (including all of those which did not show elevated p53 protein levels) were
screened for the presence of human papillomavirus types 16 and 18 and were found to be negative.
These results are discussed in relation to the pathogenesis of SCC and the immortalisation of human
keratinocytes in vitro.
In recent years several lines of evidence have characterised
p53 as a tumour suppressor gene. There is a frequent loss of
heterozygosity at the p53 locus in many types of human
tumour which might suggest a reduction to homozygosity of
mutated, deleted or rearranged p53 alleles in these cases
(Fearon et al., 1987; Yokota et al., 1987; Vogelstein et al.,
1988; Baker et al., 1989; Weston et al., 1989). Furthermore,
alterations within the coding sequence of the p53 gene are
commonly observed in human cancers (Nigro et al., 1989, see
Hollstein et al., 1991; Caron de Fromentel & Soussi, 1992 for
reviews) including squamous cell carcinomas (SCC) of the
lung (Chiba et al., 1990) oesophagus (Hollstein et al., 1990)
anus (Crook et al., 1991b), larynx (Maestro et al., 1992), oral
cavity (Brachman et al., 1992) and epidermis (Brash et al.,
1991, Pierceall et al., 1991). Additionally, it is known that
many mis-sense p53 mutations induce changes of a probable
conformational nature, which increase the half-life of the
protein from 20 m (Oren et al., 1981) to several h (Finlay et
al., 1988). As a consequence of this the p53 protein is
rendered unusually detectable by conventional Western blot-
ting and immunocytochemical techniques. Significantly, in-
creased p53 protein levels have also been reported in a wide
range of human tumours (Cattoretti et al., 1988, van der
Berg et al., 1989, Bartek et al., 1990a,b, Iggo et al., 1990,
Rodrigues et al., 1990) including SCC (Field et al., 1991,
Bennett et al., 1991, Gusterson et al., 1991; Maestro et al.,
1992). The case for p53 as a suppressor gene is further
strengthened by the examples of Li-Fraumeni Syndrome
(LFS) patients who are predisposed to several cancer types
(Li & Fraumeni 1969) and also carry germ-line p53 muta-
tions (Malkin et al., 1990, Srivastava et al., 1990, Law et al.,
1991). Some of these LFS patients have also been shown to
be heterozygous for the p53 mutation in the somatic tissue
but homozygous for the same mutation in the tumour tissue
(Malkin et al., 1990). Furthermore, fibroblasts from LFS
individuals are predisposed to spontaneous in vitro immor-
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talisation and neoplastic progression (Bischoff et al., 1990,
1991).
Experimental evidence to support p53 as a tumour supp-
ressor comes from the observation that the wild type p53
gene, but not certain mutants, can exert a reversible
(Michalovitz et al., 1990) growth suppressive effects. Further-
more, this inhibition of cell proliferation by p53 is specific to
transformed cells which harbour an altered p53 gene (Finlay
et al., 1989) including those derived from human tumours
(Baker et al., 1990, Mercer et al., 1990; Diller et al., 1990;
Casey et al., 1991). In other instances, the wild type p53 gene
can suppress human tumour formation from xenografts
(Chen et al., 1990; 1991, Cheng et al., 1992). It has also been
shown that mice which are homozygous for a null p53
mutation are prone to early spontaneous tumour develop-
ment, indicating that loss of p53 function is enough to con-
tribute to tumour development (Donehower et al., 1992).
Further support for viewing p53 protein as a tumour
suppressor comes from the observations that it is bound (and
presumed to be inactivated) by SV40 large T (Lane & Craw-
ford, 1979; Linzer & Levine, 1979), adenovirus 5 EIB (Sar-
now et al., 1982) and human papillomavirus (HPV) E6 pro-
teins (Werness et al., 1990; Crook et al., 1991a), and may
even be inactivated by degradation in the case of HPV16 and
HPV18 (Scheffner et al., 1990; Crook et al., 1991a). The last
two viruses are of particular significance to our study since
they have been reported to occur in both normal and malig-
nant tissue of the oral cavity (Maitland et al., 1987; 1989,
Yeudall & Campo, 1991). In addition, transfection of these
viruses in vitro into human keratinocytes from both the
epidermis (Pirisi et al., 1987; Kaur & McDougall, 1988) and
the oral cavity (Park et al., 1991) leads to their immortalisa-
tion, and both the E6 and E7 proteins are important for this
process (Hawley-Nelson et al., 1989; Munger et al., 1989).
Such immortalised keratinocytes readily progress to malig-
nancy (Hurlin et al., 1991).
In addition to the evidence supporting a role for p53 as a
tumour suppressor gene there is also evidence that some 'gain
of function' p53 mutations (Halevy et al., 1990) can give the
cells which possess them a growth advantage even in the
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absence of wild type p53 protein (Wolf et al., 1984; Chen et
al., 1990). Therefore, if the role of p53 mutations in the
pathogenesis of SCC is to be understood, the availability of
well characterised cell lines carrying p53 alterations would
make an important contribution, particularly if the same p53
alterations could be detected in the tumours from which the
cell lines were derived (see Sakai & Tsuchida 1992). In this
article we report the frequent detection ofp53 mutations and
elevated levels of protein in SCC of the epidermis and oral
cavity as well as in a series of SCC cell lines which are shown
to lack detectable HPV16 and 18 DNA. In six of the cell
lines we also show that the p53 mutations present in vitro are
also present in vivo.
Materials and methods
Cell culture and SCC cell lines
Human epidermal keratinocytes were prepared from infant
foreskin samples as described (Parkinson et al., 1986) and
grown in Dulbecco's modified Eagle medium (DMEM) con-
taining 20% foetal bovine serum (a selected lot), 0.4figml-I
hydrocortisone (Rheinwald & Green, 1975) and 10 ngml-'
cholera toxin (Green, 1978) in the presence of lethally
irradiated Swiss 3T3 fibroblasts (Rheinwald & Green, 1975).
Human foetal fibroblasts were prepared by collagenase diges-
tion of whole skin fragments and were cultured in the same
medium. All of the SCC lines were cultivated in the presence
of lethally irradiated 3T3 cells in DMEM, containing the
optimum concentration of foetal bovine serum and 0.4 fig
ml-' hydrocortisone. Lines SCC-4 to SCC-27, BICR-3, 6, 10,
16 and 19 grew optimally in 10% v/v foetal bovine serum,
BICR-7 in 5% v/v foetal bovine serum and BICR-18 and
BICR-22 in 2% foetal bovine serum. The properties of the
SCC lines are listed in Table II. The squamous origin of the
lines was confirmed by electron microscopy to reveal des-
mosomes and stratification and by the immunocytochemical
detection of cytokeratins and involucrin (Rheinwald &
Beckett 1981; Edington et al. - manuscript in preparation).
Tumour collection and TNM staging
Surgically removed SCC of the head and neck region were
bisected and placed either into culture medium for the
derivation of cell lines or snap frozen to obtain sections for
histology and/or immunocytochemistry. The tumours were
staged using the UICC TNM convention (UICC, 1987). All
the tumours described were confirmed as being SCC by the
Pathology Department, Glasgow Royal Infirmary and all
biopsies contained SCC material.
Immunocytochemistry
Cells were grown on chamber slides (LabTek, Nunc) prior to
rinsing with calcium and magnesium-free phosphate buffered
saline (CMF-PBS) and fixation. Both cryostat tissue sections
and cells were fixed for 20 min in 100% methanol on ice
prechilled to - 20°C overnight (Gusterson et al., 1991) fol-
lowed by air drying for 40 min. Endogenous peroxidase
activity was quenched by incubating the samples at room
temperature for 10 min in 3% v/v hydrogen peroxide (Sigma)
in methanol. The samples were then rinsed twice (10 min
each) in CMF-PBS pH 7.4 prior to blocking for 30 min with
10% normal goat serum (Vectastain, Peterborough, UK).
The specimens were then incubated for I h at room tem-
perature with the mouse monoclonal antibody p1801 (Cam-
bridge Bioscience, UK), which is known to recognise both
mutant and wild type proteins (Banks et al., 1986), at
3 tg ml' in CMF-PBS containing 0.1% crystalline bovine
serum albumin. The antigens were then visualised by treat-
ment of the specimens with biotinylated second antibody
followed by streptavidin as supplied in the Vectastain ABC
kit (Vectastain, Peterborough, UK).
After the final rinse in CMF-PBS pH 7.6 containing 0.15 M
NaCI and 0.05% Tween 80 the cells or sections were
incubated with 0.6 mg ml' diaminobenzidine (Sigma) and
0.06% hydrogen peroxide (Sigma) in CMF-PBS pH 7.4 for
7-8 min. The specimens were then rinsed in distilled water,
mounted in Aquamount (BDH Chemicals, Poole U.K.) and
sealed in nail varnish. Alternatively, some tumour sections
were stained with haematoxylin and eosin, dehydrated,
cleared and mounted in DPX mounting medium (BDH
Chemicals). The specimens were photographed with
Panotomic X film under phase contrast optics or bright field
optics. A green filter was used for the immunoperoxidase
samples photographed without counterstain. No staining was
ever seen when the first antibody was omitted.
Western blotting
Cells were harvested from subconfluent (50-80%) plates
using trypsin and EDTA, pelleted through serum-containing
medium, rinsed twice with CMF-PBS and extracted by the
method of Scheffner et al. (1991). Proteins were measured
using a Bio-Rad protein determination reagent using bovine
serum albumin as a standard and the samples (50fg/lane)
were separated alongside Rainbow marker proteins on a 15%
SDS polycrylamide gel prior to transfer to a nylon filter
(Hybond C Super, Amersham) using the Bio-Rad semi-dry
blotter. After washing in Tris-buffered saline (TBS) pH 8.0
the filters were stained in Ponceau's solution (Sigma) for
5 min and destained for 5 min in 5% v/v acetic acid to check
the consistency of transfer and loading. The filter was
blocked at 4°C overnight with staining in TBS and 0.1%
Tween 20 (TBST) containing 5% v/v milk fat protein
(TBSTM). Following this the filter was incubated at room
temperature with p1801 antibody (1 ygml-') in TBSTM,
rinsed in TBSTM, and incubated with peroxidase-conjugated
anti-mouse immunoglobulin (Amersham). After further rins-
ing the filter was dipped in luminol solution (ECL, Amer-
sham) for one minute and exposed to Kodak X-Omat fast
film for 5 min prior to development. Human epidermal
keratinocytes and fibroblasts were used as controls for nor-
mal p53 levels, JW-2 as a p53 null control and HT29 as a
positive control. All films were exposed so that the HT29
positive control produced the same intensity of signal in each
blot.
Nucleic acid isolation
RNA was extracted from exponentially growing cells using
RNAzol B (Cinna/Biotecx), subjected to two ethanol
precipitations and stored in aqueous solution at - 70°C.
Genomic DNA was isolated directly from tumour cryostat
sections by lysis of individual sections with 100tlI of lysis
buffer containing 10 m Tris-HCI, 10 mM EDTA, 10 mM
NaCl, 4% N-lauryl sarcosine and 2.75 mg ml-' proteinase K,
followed by overnight digestion at 37°C and EtOH precipita-
tion. The resulting pellet was washed with 80% EtOH, dried,
resuspended in 60 tlI TE and stored at 4°C. For PCR
amplification this DNA was diluted 1/10 with TE. Genomic
DNA was also isolated from cell lines by lysis with 4M
guanidinium thiocyanate followed by differential centrifuga-
tion through CsCl solutions, proteinase K digestion, then
phenol extracted and EtOH precipitated. This DNA was
stored in aqueous solution at 4°C and used to check the
mutations found in mRNA in some cases.
Primers
PCR and sequencing primers A, B, D, E and G were those
described by Rodrigues et al. (1990). Downstream PCR
primers E and G were 5' biotinylated during synthesis.
For PCR amplification and sequencing of DNA the
primers described by Brash et al. (1991) were used, the
downstream primer of each pair being 5' biotinylated during
synthesis (see Figure 6).
The full list of primers was, as follows:
A: 5'CAGCTCCTACACCGGCGGCCCCTGCACCAG3'1276 J.E. BURNS et al.
B: 5'CCTGTCCCTTCCCAGAAAACC3'
D: 5'TAGTGTGGTGGTGCCCTATGAGCCG3'
E*: 5'biotin-GAGCCAACCTCAGGCGGCTCTCATAGGG
CACC3'
G*: 5'biotin-GTGGGAGGCTGTCAGTGGGGAACAA3'
K: 5'CTACAAGCAGTCACAGCACAT3'
L: 5'AGAAGAAACCACGGATGGAG3'
Brash2U: 5'ACTGCCTTCCGGGTCACTGC3'
MA1: 5'TCCACGACGGTGACACGCTT3'
CC2*: 5'biotin-AAGGGACAGAAGATGACAGG3'
Brash5U: 5'TTCCTCTTCCTGCAGTACTC3'
Brash5D* 5'biotin-GCCCCAGCTGCTCACCATCG3'
Brash6U: 5'CTGATTGCTCTTAGGTCTGG3'
Brash6d*: 5'biotin-AGTTGCAAACCAGACCTCAG3'
Brash8U: 5'AGTGGTAATCTACTGGGACG3'
Brash9D*: 5'biotin-ATTCTCCATCCAGTGGTTTC3'
The primers for the amplification of HPV-16 and HPV-18
have been described previously (Yeudall & Campo, 1991)
and amplify fragments of the E6/E7 (HPV-16) or E6 regions
(HPV-18) which are 165 and 99bp respectively.
The HPV16 primers were as follows:
5'TTAATTAGGTGTATTAACTG3'
5'TGCATGATTACAGCRGGGTT3'
The HPV18 primers were as follows:
5'ATCTGTGTGCACGGAACTAAC3'
5'AATGCAAATTCAAATACCTC3'
The HPRT primers were as follows:
Primer 1 5'CTTGCTGGTGAAAAGGACCC3'
Primer 2 5'GTCAAGGGCATATCCTACAA3'
These primers produce a PCR product of 275 bp.
SiHa DNA (Single copy HPV-16), W12 (HPV-16) and
HeLa (HPV-18) were used as positive controls (see Pater &
Pater, 1985) and each PCR reaction was carried out at least
five times.
PCR amplification
For p53 amplification first strand cDNA was synthesised
from 1 fig of total cellular RNA using a Perkin-Elmer Cetus
RNA PCR kit, using random hexamers as primers. After the
addition of Taq polymerase and 0.15 .LM each PCR primer,
amplification proceeded for 35 cycles of 95°C for 1 min and
60°C for 1 min + 2 s extension per cycle. Reaction conditions
were as specified by the manufacturer.
Genomic DNA was amplified using a Perkin-Elmer Cetus
PCR kit using the following conditions:
Exon 5: Buffer J (Brash et al. 1991)
Exon 6: Buffer J (Brash et al. 1991)
Exons 8/9: Buffer supplied with PCR kit
Amplification was carried out for 35 cycles of 94°C for 30
seconds, 55°C for 1 min, 72°C for 1 min.
For HPV-16 and HPV-18 amplification 0.5 ytg genomic
DNA and 2.5 U Taq DNA polymerase were used in a total
reaction volume of 50 il. Final concentration of other
reagents were 200 flM dATP, dTTP, dGTP and dCTP; 10 mM
Tris-HCI (pH 6.3); 50 mM KCI; 1.5 mM MgCl2, 0.001%
gelatin, 0.8 LM HPV primers and 40 mM HPRT primers.
The conditions were as follows 94°C prior to enzyme addi-
tion for Omin, then 30 cycles of 94°C 1 min, 51°C 1 min,
72°C 1 min followed by Omin at 72°C.
Fifteen glI of each reaction product were run on a 6%
polyacrylamide gel along with a pX marker ladder. The gel
was stained with ethidium bromide and photographed.
Sequencing
Single-stranded PCR products were purified using Dynal M-
280 Streptavidin beads (Dynal UK Ltd) and stored at
- 20°C in aqueous solution. Both biotinylated and non-
biotinylated strands were isolated but only biotinylated prod-
ucts were found to give satisfactory sequencing results
routinely.
Direct sequencing of single-stranded PCR products was
carried out by the dideoxy chain termination method using a
Sequenase 2.0 kit (United States Biochemical). Reaction pro-
ducts were analysed in 8% polyacrylamide gels. At least two
independent PCR products were sequenced in each case. In
the case of six BICR samples both cell line and tumour
material was sequenced.
Results
Immunocytochemical detection ofp53 protein in SCC and
SCC cell lines
Table I shows the results obtained when frozen sections of
SCC from various head and neck sites were tested for overex-
Table I Immunocytochemical detection of p53 by monoclonal antibody p1801 in human squamous cell carcinomas
Stage Treatment
Tumour designation Site (TNM) prior to surgery pl801 Reactivity Total positive
BICR-1 Tongue T2NoMo None +
BICR-2 Tongue T1NoMO None
BICR-4 Tongue T4N2CMO None +
BICR-5 M Tongue T4N2CMO None +
BICR-7 Tongue T4N2BMO None +
BICR-l1 Tongue T3NoMo None - 4/12
BICR-16 R Tongue T2NOMO Surgery and DXT
BICR-20 Tongue T2NoMo None
BICR-21 Tongue T4N3MO None
BICR-22 M Tongue T4N3Mo None
BICR-23 Tongue T4N2BMO DXT
BICR-24 Tongue T112NoMo None
BICR-19 Epidermis N/A None - 0/1
BICR-3 Alveolus T2N2BMO None +
BICR-12 Alveolus T4N3Mo None 1/2
BICR-6 Hypopharynx T4N1Mo None
BICR-15 Larynx T3NoMO None + 1/4
BICR-17 Larynx T4N1Mo None
BICR-18 M Larynx T4NIMO None
BICR-9 Retromolar T3NoMo None + 1/1
BICR-10 R Buccal Mucosa T4NoMo Surgery and DXT 0/1
BICR-8 Floor of mouth T4N2BMO None
BICR-13 R Floor of mouth T4NIBMO Calcium implant + 1/3
BICR-14 R Floor of mouth T3N2BMO Radiotherapy
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pression of p53 protein. Altogether 8/24 tumours (33%)
stained positive (four tongue, one larynx, one retromolar,
one floor of mouth and one alveolus) and in the three cases
where both the primary tumour and the corresponding
lymph node metastases from the same patient were available
for study the results obtained with the primary and metas-
tatic lesions were the same (see also Figure 1). The staining
was nuclear in all cases as reported previously (Gusterson et
al., 1991; Maestro et al., 1992).
Eighteen SCC cell lines, including eight established from
the above tumours (Table II, Figure 2), were also studied for
the presence of elevated levels of p53 protein. Nine out of
eighteen lines showed positive nuclear staining including 2/8
newly established cell lines from the above tumours (Table
III). In these eight cases there was total agreement between
the results obtained with a given cell line and the tumour
from which is was derived (Table III). When protein samples
obtained from the cell lines were analysed by Western blot-
ting high steady state levels of p53 protein were observed
only in the cell lines that showed a nuclear immunocyto-
chemical staining pattern with p1801 (Figure 3, Table III).
Direct sequencing of the p53 coding region in SCC cell lines
and tumours
As there are other possible mechanisms by which p53 protein
could be stabilised other than by mutation we isolated
mRNAs from several of the positively staining cell lines and
subjected them to reverse transcription followed by PCR
amplification and direct sequencing. All of these cell lines
were found to contain point mutations or in-frame deletions
within the coding region of the p53 gene (Table IV). Figure 4
shows the comparison of a mutant (CGC-*CAC) p53
sequence found at codon 175 (arg-*his) in line SCC-27
(Figure 4(a) as compared to the same region of wild type
sequence found in line SCC-4 (Figure 4(b)). Of the thirteen
mutations, eleven were apparently homozygous mutations
since there was no evidence of expression of the normal p53
allele and seven of the point mutations have been described
previously in other human tumours or cell lines (see Hollstein
et al., 1991; Caron de Fromental & Soussi, 1992 for reviews).
We have also confirmed the mutation in line SCC-13
previously reported by Brash and co-workers (Brash et al.,
1991).
As with many p53 point mutations four of the seven
(including SCC-13) resided within the conserved domains of
the protein but one other occurred at codon 146 and two
others at codon 151 in a region (amino acids 144-166) which
has recently been suggested to be a 'hot spot' for tumours of
non-small cell tumours of the lung (Mitsudomi et al., 1992).
Even more interestingly, all three of these mutations occurred
in cell lines derived from SCCs of the tongue and all occur-
red at runs of Gs. The G-*A transition at codon 151 (Proline
to Histidine) has also been observed previously in an SCC of
the epidermis (Brash et al., 1991).
Five of the mutations were GC to AT transitions including
one in line SCC-27 (from a metastatic vulval carcinoma) at a
CpG site (Rideout et al., 1990; Jones et al., 1991). Three
mutations were transversions; one GC-*CG (BICR-3), one
GC-*TA (BICR-7) and one AT-*CG (SCC-12 Clone B).
The eighth mutation, which occurred in a clone of the line
SCC-12 originally derived from the facial epidermis of a
kidney transplant patient (SCC-12 clone B; Rheinwald &
Beckett, 1981; Parkinson et al., 1983) is, to our knowledge, a
novel T-*G transversion at the second base of codon 216
which results in the substitution of valine with glycine. Of
further interest is the observation that unusually the normal
p53 allele was still expressed in SCC-12 Clone B. A non-
tumorigenic sibling clone from the same tumour SCC-12
Clone F was shown to contain reproducibly less p53 protein
as detected by Western blotting (Figure 3 compare lanes 4
and 8) and expression of the mutant p53 sequence was very
difficult to detect in this clone although both alleles were
present. This might reflect an imbalance in the expression of
mutant and wild type p53 alleles in different clones of line
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Figure 1 Immunocytochemical detection of p53 protein in SCC
frozen sections. Examples of cross-sections of invading portions
of primary tongue SCCs BICR-1 a, BICR-4 b, and a lymph node
metastasis BICR-4, BICR-5 c, stained using horseradish perox-
idase catalysed visualisation of the monoclonal antibody p1801
(Banks et al., 1986) using diamino benzidine. Bar = 35pM;
BV = Blood vessel; m = Mesenchyme; LN = Lymph node tissue.
Note the absence of p53 staining in the more mature areas of
tumour BICR4 (arrow).
SCC-12 and this is currently under investigation. Lines
BICR-6 and BICR-16 possess stop codons at amino acids
192 and 146 and three other lines, BICR-22, SCC-25 and
BICR-19 possess out of frame 19 bp, 2 bp and 107 bp dele-
tions spanning codons 308 +, 209+ and exon 10 respectively.
A stop codon also resulted from the frame shift at codon 345
in line BICR22. Expression of a completely normal p53 allele
in line BICR-19 was also detected. None of these five lines
displayed elevated levels of p53 protein.
Absence ofdetectable HPV16 and HPV18 DNA in SCC cell
lines
As it is possible that in the nine SCC lines we have studied
where there is no elevation in p53 protein levels, p53 is being1278 J.E. BURNS et al.
Table II Squamous cell carcinoma cell lines used in this study
Site Treatment
Cell line designation (TNM) Stage prior to surgery Squamous origin Tumorigenicity
SCC-4 Tongue Unknown Radiation Yes Yes
SCC-9 Tongue
SCC-12 Clone B
SCC-13
SCC-15
SCC-25
SCC-27 M
BICR-3
BICR-6
BICR-7
BICR-10 R
BICR-16 R
BICR-18 R
BICR-19
BICR-22 M
BICR-31
BICR-37 M
BICR-56
Facial epidermis
Epidermis
Tongue
N/A
N/A
Methotrexate
None
None
Yes Yes
Yes
Radiation Yes
Unknown None
Tongue
Vulva N/A
(Peritoneal Metastasis)
Upper Alveolus T2N2
Hypopharynx
Tongue
Buccal Mucosa
Tongue
Larynx
(Lymph Node
Metastasis)
Ear Epidermis
Tongue
(Lymph Node
Metastasis)
Tongue
Tongue
(Lymph Node
Metastasis)
Tongue
T4N1Mo
None
Yes
Yes
Unknown Yes
2BMO None
None
T4N2BMo None
T4NOMO
T2NoMo
T4N1Mo
N/A
T4N3MO
T4N2BMO
T4N2CMO
T4NIMo
DXT
DXT
None
None
None
None
None
None
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
N.d
N.d
N.d
Yes
Yes
Yes
Yes
N.d
No
Yes
N.d
Yes
Yes
Yes
Yes
Yes
Yes
N.d
Yes
Reference
Rheinwald &
Beckett 1981
Rheinwald &
Beckett 1981
Rheinwald &
Beckett 1981
Rheinwald &
Beckett 1981
Rheinwald &
Beckett 1981
Rheinwald &
Beckett 1981
Parkinson et al.,
1983
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
Unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
Edington &
Parkinson
unpublished data
R = Derived from recurrent tumour DXT = Deep X-ray Therapy.
Table III Immunocytochemical localisation of p53 protein using monoclonal antibody p1801
Positive staining p53 protein detectable by Western blot
Cell line tumour for p53 cell line Tumour Cell line
SCC-4 + N.d +
SCC-9 N.d
SCC-12 Clone B + N.d +
SCC-13 + N.d +
SCC-15 N.d
SCC-25 N.d
SCC-27 + N.d +
BICR-3 + + +
BICR-6
BICR-7 + + +
BICR-10 - -
BICR-16 - - -
BICR-18 - - -
BICR-19 - - -
BICR-22 - -
BICR-31 + N.d NAd
BICR-37 + N.d Nd
BICR-56 + N.d N.d
M = MetastasisP53 ALTERATIONS IN HUMAN SQUAMOUS CELL CARCINOMAS AND CELL LINES 1279
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Figure 2 Immunocytochemical detection of mutant p53 proteins in SCC cell lines. Cell lines stained with antibody p1801 followed
by horseradish peroxidase as detailed in Figure 1. The cells were photographed under phase contrast optics (a.c.e) and then again
under bright field optics (no counterstain-b,d,f). Panels a and b, SCC-4; panels c and d, SCC-9; panels e and f, BICR-3. No
staining was seen when the first antibody was omitted. Bar = 31 pM.
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Figure 3 Western blotting of SCC p53 proteins. Western blots of NP40-extracted proteins from normal human keratinocytes and
15 of the SCC cell lines. Human fibroblasts and JW/2 colon carcinoma cells were used as controls for normal levels of and no p53
protein respectively. HT29 colon carcinoma was included as a control line which was known to express high levels of p53 protein
(Rodrigues et al., 1990). Lanes 1, 20 and 22, HT29 (positive control); Lane 2, Human embryo fibroblasts (normal control); Lane 3,
SCC-27; Lane 4, SCC-12 clone F; Lane 5, SCC-13; Lane 6, SCC-25; Lane 7, SCC-15; Lane 8, SCC-12 clone B; Lane 9, SCC-9;
Lane 10, SCC-4; Lanes 11 and 19, JW/2 (negative control); Lane 12, normal human epidermal keratinocytes; Lane 13, BICR 22;
Lane 14, BICR 19; Lane 15, BICR 16; Lane 16, BICR 10; Lane 17, BICR 6; Lane 18, BICR 3; Lane 21, BICR 7. The upper arrow
of each panel shows the position of the 68 kd molecular weight marker and the lower arrow shows the position of the 43 kd
marker. When the antibody was omitted no signal could be detected.
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Figure 4 Direct sequencing of PCR-amplified, reverse transcribed p53 mRNA: a, SCC-27 showing codon 175 G-*A mutation. b,
Wild type sequence in the same region (SCC 4). c, SCC-12 clone B showing expression of wild-type (T) and mutant (G) alleles at
codon 216. Arrows marks positions of mutant bands.
Table IV p53 Mutations detected in squamous cell carcinomas and cell lines
Base Expression of Region sequenced
Cell line Codon Mutation Amino acid change change normal allele (codons)
SCC-4 151 CCC+TCC pro+ser C+T No 105-393
SSC_9b 274-285 32 bp deletion 285+ out of frame No Jung et al. (1992)
SCC-25 209 2 bp deletion 209+ out of frame - No 171-217
SCC-12 Clone B 216 GTG-*GGG val-*gly T->G Yes 1-393
SCC-13 258 GAA-*AAA glu+lys G+A No 105-393
SCC-27 175 CGC-*CAC arg-*hist G->A No 105-393
BICR-3a 282 CGG-*CCG arg-*pro G->C No 105-383
BICR-6 192 CAG+TAG glu-*stop C-*T No 105-393
BICR-7a 151 CCC+CAC pro-his C+A No 105-393
BICR-10 None detected 1 -331
BICR-16a 146 TGG+TGA trp+stop G-*A No 105-228
BICR-18 None detected 2-96; 171-335; 342-393
BICR-19 exon 10 deleted 107 bp deletion 332+ out of frame - Yes 1-393
BICR-22a exon 8/9 19 bp deletion 308+ out of frame->345 No 2-335
splice site stop
BICR-31a 173, 174 3 bp deletion val arg-*gly TGA del. No 2-335
BICR-56a 126-132 21 bp deletion 7aa deleted - No 111-228
aAlso detected in the original tumour sample bData from Jung et al. (1992).
inactivated by degradation after complexing with an HPV
virus such as HPV16 or HPV18 (Werness et al., 1990;
Scheffner et al., 1990; Crook et al., 1991a), we screened our
cell lines for the presence of these viruses.
All of our cell lines were screened for the presence of
HPV16 and 18 DNA by PCR, using DNA from the cell line
SiHa as a positive control for a single copy of integrated
HPV16 DNA. W12 and HeLa were used as further positive
controls for HPV16 and 18 respectively. HPV-compatible,
hypoxanthine guanosine phosphoribosyl transferase (HGPRT)
primers were used to control for the integrity of each DNA
sample and produced a band of approximately 275 bp in all
of the SCC samples (Figure 5). Figure 5 also shows that in
all of the SCC lines which stained negatively for p53 protein
the 165 bp HPV16 and 99 bp HPV18 PCR products were
absent. The faint band in the BICR16 track was not re-
producible and was in any case too large to be the HPV16
product. This product may be indicative of a low copy
number of another closely related HPV type and this is
currently being investigated. Other HPV types which have
been reported from the oral cavity such as HPV6, HPV-11
(Loning et al., 1985) and HPV-4 (Yeudall & Campo, 1991)
are also undetectable in lines SCC-4, SCC-9, SCC-12B, SCC-
12F, SCC-13, SCC-15 and SCC-25 (M. Stanley-personal
communication; A. Yeudall-personal communication).
These data do not therefore support a role of these viruses in
the inactivation of p53 in our series of SCC cell lines.
Discussion
We have confirmed the earlier reports of Field et al. (1991),
Gusterson et al. (1991) and Maestro et al. (1992) that
4 S) t ; 9 1 0 1
a-
b-
c -
d-
Figure 5 HPV screening of BICR cell lines. Lane 1, pX 174
HaeIII digested DNA molecular weight markers; lane 2,
bacteriophage A DNA positive control; lane 3, HeLa genomic
DNA; lane 4, W12 genomic DNA; lanes 5-11, genomic DNA
from BICR cell lines 3, 6, 10, 16, 18, 19 and 22 respectively. Band
A represents the bacteriophage A PCR product, B the HPRT
gene PCR product, C the HPV 16 PCR product and D the HPV
18 PCR product.
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Figure 6 Primers used for PCR of human p53 segments and the
distribution of mutations found in SCC cell lines.
elevated levels of p53 protein are common in SCCs of the
epidermis and oral cavity. Using a much larger series than
that studied by Gusterson et al., we also report a high
frequency of p53 staining in cell lines established from SCCs
including eight of the SCCs that were studied in vivo.
Our results are also in agreement with the statements made
by those authors that there is no obvious correlation between
the presence of high levels of p53 protein and tumour stage
or treatment history and with the observation made by
Gusterson et al. (1991) that the most intense staining was
often observed in keratinocytes occupying a more basal posi-
tion, or at the invading edge of the tumour (Figure 1, see
also Purdie et al., 1991). These results are in keeping with a
role for p53 as a regulator of the cell cycle since in both
normal and malignant epithelia, proliferation is restricted to
the less differentiated cells.
Although in several human tumour systems a good cor-
relation has been noted between the presence of elevated p53
protein levels and the presence of mutations within the
coding region of the gene, this had not been investigated for
SCC of the epidermis and oral cavity. This is important for
the oral cavity in particular where increased p53 protein
levels could result from complexing with the HPV E6 protein
of HPV types 6 or 11 (Crook et al., 199la) or be secondary
to another oncogenic event. Indeed, helix-loop-helix proteins
have been suggested as potential regulators of p53 transcrip-
tion (Ronen et al., 1991) and one member of this protein
family (c-myc) is frequently amplified in SCC of the head and
neck (Yokota et al., 1986). Furthermore, the mdm2 oncogene
is known to bind and stabilise the p53 protein in tumours
where p53 mutations are absent (Oliner et al., 1992) and
elevated p53 levels may also be a consequence of genetic
instability (Lu et al., 1992).
We have so far sequenced the p53 coding region of 14 SCC
cell lines including eight of the nine lines which expressed
high levels of p53 protein. In all cases where elevated levels
of p53 protein were detected, mis-sense mutations, or in-
frame deletions within the coding region were found, thus
agreeing with the assertion that elevated levels of p53 protein
are a good indicator of p53 mutation, at least in carcinomas
of the head and neck region (see also Maestro et al., 1992).
In the case of the SCC of the upper aerodigestive tract, the
mutations we detected were predominantly (4/5) G-*A tran-
sitions or G-*T transversions, consistent with the known
action of benzo-(a)-pyrene and nitrosamines which are the
most abundant classes of carcinogens found in cigarette
smoke (IARC 1986, see also Maestro et al., 1992). These
observations are consistent with cigarette smoking being a
major aetiological factor in the generation of these tumours
(Stell, 1972). We also noted that many of the mutations or
deletions detected in SCCs of the tongue (3/7) occurred
within the region (codons 144-166) which has been reported
to be a hot spot for non-small cell lung cancer (Mitsudomi et
al., 1992). Gusterson et al. (1991) also reported that one of
two tongue SCC mutations occurred within this region,
whereas (Maestro et al., 1992) did not notice any in six of the
larynx SCC mutations reported. Although the numbers are
small, this might suggest that mutations within the region
codons 144-166 are preferentially induced and/or selected at
the tongue site, but this clearly needs further investigation. In
7/8 of the cases expression of the normal p53 allele was not
detectable, thus indicating that loss of the normal p53 allele
or an elimination of its expression had occurred during
tumour progression. Normal allele expression was lost even
in the case of line SCC-4 which has a proline-*serine amino
acid substitution at codon 151 of the p53 gene. This muta-
tion has been reported to drive the wild type protein into the
mutant conformation when the two are cotranslated in vitro
(Milner & Medcalf, 1991). If this is the case in intact SCC-4
cells, some wild type p53 activity must remain in the
heterozygous state, otherwise it is difficult to explain how the
cells which had lost wild-type p53 expression gained a selec-
tive advantage in the tumour. In clone SCC-12 clone B
however, both the mutated and normal p53 alleles were
expressed. Cell line SCC-12 contains populations of tumori-
genic (e.g. SCC-12 clone B) and non-tumorigenic (e.g. SCC-
12 clone F) keratinocytes the former of which (but not the
latter) possess a defect in their ability to respond to terminal
differentiation stimuli (Rheinwald & Beckett, 1980; Parkinson
et al., 1983). Interestingly, we have found it difficult to detect
the mutant p53 allele in the non-tumorigenic clone F of
SCC-12 and this clone also contains far less p53 protein than
SCC-12 clone B (Figure 3 compare lane 4 with lane 8). The
heterozygous p53 mutation in line SCC-12 may therefore be
an example of a p53 mutation which occurred late in SCC
progression and its role in affecting keratinocyte behaviour is
currently being explored. The mutation in SCC-12 clone B is
to our knowledge novel and is of additional interest since the
T-*G transversion in the second base of codon 216 results in
the substitution of a glycine for a valine and glycine substitu-
tions have been proposed to introduce folds into amino acid
chains thus altering protein conformation (see Gordon et al.,
1988). Several other types of amino acid substitution have
previously been noted at codon 216 (Caron de Fromentel &
Soussi, 1992), indicating that this part of the p53 molecule is
a relevant site for mutagenesis.
We have also begun to investigate other possible
mechanisms of p53 inactivation in our negatively-staining cell
lines. Lines BICR-6 and BICR-16 were found to contain stop
codon mutations and lines SCC-25, BICR-19 and BICR-22
out-of-frame deletions. Line SCC-9 (Table IV) was also
recently reported to possess an out of frame deletion (Jung et
al., 1992). Since high levels of proteins were not observed in
these lines it seems that these mutant proteins were not
stabilised. This would be consistent with the absence of the
sequences required for oligomerisation at the carboxy ter-
minus (Vogelstein & Kinzler, 1992) as the epitope for
antibody p1801 is close to the amino terminus of the p53
protein (Banks et al., 1986) and should detect the truncated
proteins if they were present. The other three negatively
staining cell lines are currently being sequenced (see Table
IV) to determine whether further stop codon mutations are
present or whether mis-sense mutations that do not result in
elevated levels of p53 protein are present (Halevy et al., 1990;
Malkin et al., 1990). Both of these classes of mutations have
already been reported in SCC of the epidermis (Brash et al.,
1991; Pierceall et al., 1991) and head and neck (Sakai &
Tsuchida, 1992). Also, mutations in the non-coding region of
the gene may effect p53 transcription or translation and we
are currently examining this possibility by Northern and
Western blotting.
Finally, HPV types 16 and 18 are known to bind and
degrade the p53 protein (Werness et al., 1990; Scheffner 1990;
Crook et al., 1991a), so it is possible that any negatively-
staining cell lines harbouring these HPV types could have
inactivated p53 by this mechanism. This is particularly
relevant to oral SCC since HPV16 and 18 are known to
occur in the oral cavity (Maitland et al., 1987; 1989; Yeudall
& Campo, 1991) and can immortalise oral keratinocytes
(Park et al., 1991). Fifteen of the SCC lines under investiga-
tion (including all the negatively-staining ones) were
repeatedly screened for HPV-16 and 18 DNA by PCR and
were found to be negative. Therefore, p53 has not been1282 J.E. BURNS et al.
inactivated by these HPV types in our cell lines. Our data do
not rule out the possibility that there may be other HPV
types capable to degrading p53 which are undetectable by the
PCR primers we have used, but there is no evidence to
support the existence of such viruses at present.
It has been suggested that in vitro immortalisation is con-
nected with an important and possibly rate-limiting step in
carcinogenesis (Newbold, 1985), although this has been dis-
puted (Weinberg, 1989; Hunter, 1991). It is nevertheless in-
teresting that a high frequency ofp53 alterations are demons-
trable both in vivo (Brash et al., 1991; Pierceall et al., 1991;
Field et al., 1991; Gusterson et al., 1991, Sakai & Tsuchida,
1991; Maestro et al., 1992; Brachman et al., 1992, this study)
and in vitro (Gusterson et al., 1991; Sakai & Tsuchida, 1991,
this study) in a cell type which frequently displays the prop-
erty of in vitro immortalisation (Easty et al., 1981; Rheinwald
& Beckett, 1981). It is also noteworthy that fibroblasts
derived from individuals with the Li-Fraumeni syndrome
carrying germ-line p53 mutations are prone to spontaneous
in vitro immortalisation (Bischoff et al., 1990) and when
mouse (Harvey & Levine, 1991) or chicken (Ulrich et al.,
1992) cells spontaneously immortalise in vitro p53 alterations
are usually seen.
The current series of human SCC cell lines offer an oppor-
tunity to investigate the role of p53 in the pathogenesis of
human SCC including its possible role in cellular immor-
talisation.
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were supported by grants awarded to the Beatson Institute by the
Cancer Research Campaign.
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